Common sites for transdermal medication delivery include the upper outer arm, upper chest, upper back between the shoulder blades, and the abdomen (avoiding the waistline)
Evidence indicates that this dual therapy can effectively reduce albuminuria as a crucial surrogate marker for kidney damage, more so than monotherapy
Just as important, we have seen no major complications in patients following DMR
Vyvanse has a high potential for abuse and dependence
At 40 weeks, all three doses (3 mg, 12 mg, 36 mg) of orforglipron achieved the primary endpoint of superior A1C reduction compared to placebo , lowering A1C by 1.3% to 1.6% from a baseline of 8.0% , with improvements seen as early as 4 weeks